Century Therapeutics (IPSC) Non-Current Assets (2020 - 2026)
Century Therapeutics (IPSC) posted quarterly Non-Current Assets of $187.5 million for Q1 2026, up 28.45% year-over-year from $146.0 million in Q1 2025, and up 82.17% quarter-over-quarter from $102.9 million in Q4 2025.
Century Therapeutics (IPSC) Non-Current Assets (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported Non-Current Assets for 7 consecutive years, with $187.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 28.45% year-over-year to $187.5 million; the TTM figure through Mar 2026 stood at $522.0 million (down 25.51% YoY), while the FY2025 annual figure was $102.9 million, down 35.33% from the prior year.
- Non-Current Assets rose to $187.5 million in Q1 2026 per IPSC's latest filing, from $102.9 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $255.9 million in Q2 2023 and bottomed at $102.9 million in Q4 2025.
- Historically, Non-Current Assets has averaged $169.8 million across 5 years, with a median of $166.8 million in 2022.
- Annual changes were most pronounced in 2023 — Non-Current Assets jumped 71.97% — and 2025, when it sank 41.53%.
- Century Therapeutics' Non-Current Assets stood at $166.8 million in 2022, then rose by 10.11% to $183.7 million in 2023, then dropped by 13.35% to $159.2 million in 2024, then plunged by 35.33% to $102.9 million in 2025, then surged by 82.17% to $187.5 million in 2026.
- Business Quant data shows IPSC's Non-Current Assets at $187.5 million in Q1 2026, $102.9 million in Q4 2025, and $107.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - | 162.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 162.24 Mn |
| Mar 31, 2026 | 187.51 Mn |
| Dec 31, 2025 | 102.94 Mn |
| Sep 30, 2025 | 107.01 Mn |
| Jun 30, 2025 | 124.52 Mn |
| Mar 31, 2025 | 145.98 Mn |
| Dec 31, 2024 | 159.17 Mn |
| Sep 30, 2024 | 182.61 Mn |
| Jun 30, 2024 | 212.97 Mn |
| Mar 31, 2024 | 148.69 Mn |
| Dec 31, 2023 | 183.70 Mn |
| Sep 30, 2023 | 223.85 Mn |
| Jun 30, 2023 | 255.88 Mn |
| Mar 31, 2023 | 200.29 Mn |
| Dec 31, 2022 | 166.82 Mn |
| Sep 30, 2022 | 150.11 Mn |
| Jun 30, 2022 | 148.79 Mn |
| Mar 31, 2022 | 185.05 Mn |
| Dec 31, 2021 | 209.22 Mn |
| Sep 30, 2021 | 169.33 Mn |